Sorafenib
Back to searchMolecule Structure
Scientific Name
Sorafenib
Description of the Drug
Sorafenib is a kinase inhibitor used to treat unresectable liver carcinoma, advanced renal carcinoma, and differentiated thyroid carcinoma.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00398
http://www.drugbank.ca/drugs/DB00398
Brand Name(s)
Nexavar
Company Owner(s)
Teva Pharmaceuticals Usa Inc, Bayer Healthcare Pharmaceuticals Inc, Dr Reddys Laboratories Ltd, Mylan Pharmaceuticals Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Tyrosine-protein kinase receptor FLT3 | SINGLE PROTEIN | INHIBITOR | CHEMBL1974 |
| Stem cell growth factor receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL1936 |
| Vascular endothelial growth factor receptor | PROTEIN FAMILY | INHIBITOR | CHEMBL2095227 |
| Serine/threonine-protein kinase B-raf | SINGLE PROTEIN | INHIBITOR | CHEMBL5145 |
| Serine/threonine-protein kinase RAF | SINGLE PROTEIN | INHIBITOR | CHEMBL1906 |
| Tyrosine-protein kinase receptor RET | SINGLE PROTEIN | INHIBITOR | CHEMBL2041 |
| Platelet-derived growth factor receptor beta | SINGLE PROTEIN | INHIBITOR | CHEMBL1913 |
Clinical Trial(s)
Unichem Links
| Atlas | BAY-43-9006 | ||
| SureChEMBL | SCHEMBL8218 | ||
| PharmGKB | PA7000 | ||
| Human Metabolome Database | HMDB0014542 | ||
| DrugBank | DB00398 | ||
| PubChem: Thomson Pharma | 14834034 | ||
| PubChem | 216239 | ||
| Mcule | MCULE-6112506696 | ||
| LINCS | LSM-1008 | ||
| Nikkaji | J1.961.269D | ||
| PDBe | BAX | ||
| BindingDB | 16673 | ||
| EPA CompTox Dashboard | DTXSID7041128 | ||
| DrugCentral | 2459 | ||
| Brenda | 138692 | 10040 | 18796 |
| ChemicalBook | CB42545752 | ||
| Guide to Pharmacology | 5711 | ||
| rxnorm | NEXAVAR | SORAFENIB TOSYLATE | SORAFENIB |
| PubChem: Drugs of the Future | 12015507 | ||
| ChEBI | 50924 | ||
| ZINC | ZINC000001493878 |
